The ACA unleashed the largest wholesale change to healthcare funding in more than four
decades, impacting both reimbursement and prescribing of pharmaceutical therapies.
These changes altered how MCOs cover beneficiaries through new regulations and expanded
access via government-supported programs. As a result, nearly every individual in the United
States has been touched in some way by healthcare reform—and the impact is starting to
translate to actual reimbursement and prescribing decisions.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now